GSK’s ‘break­through’ BC­MA can­cer drug gets a pri­or­i­ty re­view — and a big win for the on­col­o­gy R&D team

Af­ter large­ly whiff­ing the past 2 years on the phar­ma R&D front, Glax­o­SmithK­line re­search chief Hal Bar­ron has seized boast­ing rights to a key win that puts them back in the can­cer drug de­vel­op­ment game.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER